Dermata Long Term Debt vs Net Receivables Analysis
| DRMA Stock | USD 1.15 0.01 0.86% |
Dermata Therapeutics financial indicator trend analysis is much more than just examining Dermata Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Dermata Therapeutics is a good investment. Please check the relationship between Dermata Therapeutics Long Term Debt and its Net Receivables accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.
Long Term Debt vs Net Receivables
Long Term Debt vs Net Receivables Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Dermata Therapeutics Long Term Debt account and Net Receivables. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Dermata Therapeutics' Long Term Debt and Net Receivables is 0.94. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Dermata Therapeutics, assuming nothing else is changed. The correlation between historical values of Dermata Therapeutics' Long Term Debt and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Dermata Therapeutics are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Long Term Debt i.e., Dermata Therapeutics' Long Term Debt and Net Receivables go up and down completely randomly.
Correlation Coefficient | 0.94 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Long Term Debt
Long-term debt is a debt that Dermata Therapeutics has held for over one year. Long-term debt appears on Dermata Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Dermata Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Net Receivables
Most indicators from Dermata Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Dermata Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.At present, Dermata Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 6.9 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (21.65).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 45.6K | 63.6K | 57.2K | 111.4K | Depreciation And Amortization | 14.1K | 9.7K | 8.0M | 8.4M |
Dermata Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Dermata Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Dermata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dermata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dermata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dermata Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.35) | Return On Assets (0.91) | Return On Equity (1.73) |
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.